Oncology
A breakthrough technology for tumour-naïve testing
Built on proprietary cfDNA enrichment technology, our multimodal platform is enabling the development of more sensitive diagnostic tests across an expanding range of clinical applications, from cancer screening to minimal residual disease (MRD) monitoring.
An innovative cfDNA-based platform
From a single blood sample, we enable seamless multimodal profiling of cancer-specific methylation, fragmentomic and mutation markers. This is enabled by our proprietary chemoenzymatic platform for enrichment of highly informative unmethylated ctDNA fragments.
Sophisticated machine learning infrastructure
Tagomics has developed proprietary machine learning algorithms that reveal cancer signals hidden in blood. Using our cloud-based pipelines to scale feature extraction, model training and inference, we uncover highly cancer-specific biomarkers.
Improved accuracy and insights
Our integrated, multilayered machine learning models build a picture of disease state for improved accuracy in early cancer detection and MRD.
Key advantages
- Tumour-naive approach for MRD
- Tailored to indication and application needs
- Ultra-low sample input
- Epigenomic, genomic and fragmentomic insights from a single blood sample
- Seamless integration with existing genomics workflows
Our workflow
Enhance your assays
Tagomics is shaping the future of tumour-naïve profiling. Get in touch to partner with us and develop the next generation of oncology diagnostics.
Contact us
Press releases
The Scientist | Innovation Spotlight: unlocking better diagnostics through multiomic biomarkers
Robert Neely from Tagomics shares how simultaneous genomic and epigenomic profiling can drive more precise and timely healthcare.
Press releases
Drug Discovery News: could we diagnose cancer earlier than ever before?
Methylation profiling of cell-free DNA is opening new possibilities for detecting cancer at its earliest, pre-symptomatic stages, offering a potential breakthrough in how and when disease is found.
Press releases
Technology Networks: academic origins driving impact in epigenetic diagnostics
Non-destructive analysis offers simultaneous genomic, epigenomic and fragmentomic information from a single sample. Karen Steward, PhD speaking with Rob Neely, PhD & Mark Garner, PhD.
Press releases
Medlespod podcast with CSO Rob Neely
Tagomics Wins NHS Grant, Unveils De-Methylation Platform for Early Cancer Testing with Rob Neely, CSO
Press releases
Tagomics Seeks Unmethylated Genomic Regions as Part of Data Package for Drug Development
Tagomics, a UK-based startup, has recently emerged from stealth with a new way to look at methylation, or lack thereof, in the human genome.
Press releases
Tagomics awarded £860k Innovate UK Biomedical Catalyst grant for detection of colorectal cancer
- Grant forms part of £1.2M project to customise Tagomics’ multiomic profiling platform for early detection of colorectal cancer.
- Early detection test to be developed in collaboration with the Salford Royal NHS Foundation Trust and the Northern Care Alliance Research Collection biobank.
Press releases
Calculus leads £6.7m funding round into Tagomics
Tagomics, developers of a cutting-edge platform for comprehensive disease insight and diagnosis, today announces a £6.7m funding round. This achievement follows a £1.6m pre-seed round led by IQ Capital and Start Codon and including grant funding from Innovate UK.
Scientific publications
JCO Precision Oncology: Cell-Free DNA to Detect and Monitor Toxicity Signals
Tagomics’ Organ Health Programme Lead Dr John Gallon, Scientific Advisory Board member Professor Yuval Dor, and our partners at AstraZeneca have co-authored a paper recently published in JCO Precision Oncology exploring the next frontier in cfDNA applications: precision drug safety monitoring.
Scientific publications
Tagomics publishes a new approach to genome-wide epigenomic profiling
- Study published in ‘Cell Reports Methods’ demonstrates the strength of Tagomics’ platform for epigenomic biomarker discovery and applications in liquid biopsy
- Activace platform enables targeted, genome-wide profiling of unmethylated DNA regions, providing a comprehensive view of the epigenome that can be scaled to the study of large patient cohorts
Press releases
Tagomics Announces a Multiomic Profiling Co-Marketing Agreement with Agilent
Exclusive program will provide customers with a single, unified workflow for comprehensive genomic profiling and genome-wide epigenetic analysis.